# Financial News Report on Johnson & Johnson (JNJ) Stock as of September 16, 2024

## Introduction

Johnson & Johnson (NYSE: JNJ) is a global leader in the healthcare sector, with a diverse portfolio that spans pharmaceuticals, medical devices, and consumer health products. As of September 16, 2024, JNJ's stock performance, financial health, and strategic initiatives have been under close scrutiny by investors and analysts alike. This report provides a comprehensive analysis of JNJ's stock performance, key financial metrics, recent developments, and future outlook.

## Stock Performance

### Year-to-Date Performance

At the beginning of 2024, JNJ's stock was trading at $156.74. As of the latest data, the stock has appreciated by 5.6%, reaching $165.52 ([MarketBeat](https://www.marketbeat.com/stocks/NYSE/JNJ/)). This performance is notable given the broader market conditions and the competitive landscape in the healthcare sector.

### Historical Performance

Over the past year, JNJ has underperformed compared to the broader U.S. market and the U.S. Pharmaceuticals industry. While the U.S. market returned 24.4% and the Pharmaceuticals industry returned 18.8%, JNJ's stock has shown a more modest return ([Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson)).

### Volatility

JNJ's stock has exhibited stable price volatility over the past year, with a weekly volatility of 2%. This stability is a positive indicator for risk-averse investors ([Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson)).

## Financial Metrics

### Valuation Measures

- **Market Capitalization**: $398.45 billion
- **Enterprise Value**: $414.46 billion
- **Trailing P/E Ratio**: 25.04
- **Forward P/E Ratio**: 15.22
- **PEG Ratio (5-year expected)**: 0.97
- **Price/Sales (ttm)**: 4.70
- **Price/Book (mrq)**: 5.57
- **Enterprise Value/Revenue**: 4.79
- **Enterprise Value/EBITDA**: 15.05 ([Yahoo Finance](https://sg.finance.yahoo.com/quote/JNJ/))

### Profitability and Income Statement

- **Profit Margin**: 43.91%
- **Return on Assets (ttm)**: 8.10%
- **Return on Equity (ttm)**: 22.15%
- **Revenue (ttm)**: $86.58 billion
- **Net Income Available to Common (ttm)**: $16.38 billion
- **Diluted EPS (ttm)**: $6.60 ([Yahoo Finance](https://sg.finance.yahoo.com/quote/JNJ/))

### Balance Sheet and Cash Flow

- **Total Cash (mrq)**: $25.48 billion
- **Total Debt/Equity (mrq)**: 58.00% ([Yahoo Finance](https://sg.finance.yahoo.com/quote/JNJ/))

## Recent Developments

### Quarterly Earnings

Johnson & Johnson reported its Q2 2024 earnings on July 17, 2024. The company posted an earnings per share (EPS) of $2.82, surpassing the consensus estimate of $2.71 by $0.11. Revenue for the quarter increased by 4.3% year-over-year ([MarketBeat](https://www.marketbeat.com/stocks/NYSE/JNJ/)).

### Strategic Initiatives

#### Split into Two Companies

In 2021, Johnson & Johnson announced plans to split into two publicly traded companies, focusing on Consumer Health and Pharmaceuticals. This move is expected to be completed by late 2023, aiming to streamline operations and enhance focus on core competencies ([MarketBeat](https://www.marketbeat.com/stocks/NYSE/JNJ/)).

#### Product Pipeline and Approvals

Johnson & Johnson has a robust pipeline with upcoming regulatory milestones for key products like RYBREVANT and TREMFYA. The company is also integrating Shockwave and expanding newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and the VARIPULSE platform ([Johnson & Johnson](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2024-results)).

### Clinical Trials and Research

#### TAR-200 Phase 2b SunRISe-1 Study

New data from the TAR-200 Phase 2b SunRISe-1 study showed an 84% complete response rate in patients with high-risk non-muscle-invasive bladder cancer. These results were presented at the European Society of Medical Oncology (ESMO) 2024 Congress ([Yahoo Finance](https://finance.yahoo.com/quote/JNJ/news/)).

#### Solid Tumor Cancer Research

Johnson & Johnson presented 11 oral presentations from its solid tumor portfolio at the 2024 World Conference on Lung Cancer (WCLC) and ESMO Congress. Key findings included new data on RYBREVANT for EGFR-mutated advanced non-small cell lung cancer (NSCLC) and its combination with chemotherapy for metastatic colorectal cancer ([Johnson & Johnson](https://www.jnj.com/media-center/press-releases/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with-new-data-at-wclc-and-esmo-2024)).

## Analyst Ratings and Forecasts

### Analyst Recommendations

According to 12 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $172.42, representing a potential increase of 4.17% from the current price ([Stock Analysis](https://stockanalysis.com/stocks/jnj/)).

### Earnings Estimates

Analysts have revised their EPS estimates downward by 10%, reflecting cautious optimism about the company's near-term performance ([Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson)).

## Dividend and Shareholder Returns

### Dividend History

Johnson & Johnson is a member of the Dividend Aristocrat Index and qualifies as a Dividend King, having increased its dividend annually for over 50 years. The company announced a quarterly cash dividend of $1.24 per share for Q3 2024, payable on September 10, 2024 ([Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson)).

### Shareholder Returns

Despite its stable dividend payments, JNJ has underperformed its industry and the broader market over the past year. However, its stable price volatility and robust pipeline offer a promising outlook for long-term investors ([Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson)).

## Conclusion

Johnson & Johnson remains a stalwart in the healthcare sector, backed by a diverse portfolio, a robust pipeline, and a strong financial position. While the stock has underperformed relative to the broader market and its industry peers, its stable price volatility and consistent dividend payments make it an attractive option for risk-averse investors. The company's strategic initiatives, including the split into two entities and ongoing clinical trials, are poised to drive future growth. Investors should keep an eye on upcoming regulatory milestones and quarterly earnings to gauge the company's performance in the near term.

## References

- MarketBeat. (2024). JNJ Stock Analysis - Frequently Asked Questions. Retrieved from https://www.marketbeat.com/stocks/NYSE/JNJ/
- Yahoo Finance. (2024). Johnson & Johnson (JNJ). Retrieved from https://sg.finance.yahoo.com/quote/JNJ/
- Johnson & Johnson. (2024). Johnson & Johnson Reports Q2 2024 Results. Retrieved from https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2024-results
- Simply Wall St. (2024). Johnson & Johnson NYSE:JNJ Stock Report. Retrieved from https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson
- Stock Analysis. (2024). Johnson & Johnson (JNJ). Retrieved from https://stockanalysis.com/stocks/jnj/
- Johnson & Johnson. (2024). Johnson & Johnson is Transforming Solid Tumor Cancer Outcomes with New Data at WCLC and ESMO 2024. Retrieved from https://www.jnj.com/media-center/press-releases/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with-new-data-at-wclc-and-esmo-2024